Assoc Prof @UCincyMedicine and PD @ #UCradonc, GI cancer focus, clinical trials and #microbiome enthusiast
Sep 25, 2020 • 10 tweets • 6 min read
Short #tweetorial on issues related to toxicity in oncology trials. How do we conclude Tx A is more/less toxic than Tx B? Room for improvement when you look at how we collect and report toxicity. Vital for both therapy escalation and de-escalation trials [Thread]
Do we consistently grade events? Answer is no for retrospective and even prospectively this is a challenge with CTCAE. High grade events also require adjudication and attribution which is inherently a challenge. Nice study here pubmed.ncbi.nlm.nih.gov/32371073/@julian_hong@mpalta1098
Aug 29, 2020 • 7 tweets • 4 min read
Sad to hear the passing of #ChadwickBoseman . Another reminder of the INCREASING problem of young patients with colorectal cancer. Debate regarding screening age in asymptotic patients aside...in young patients WITH symptoms Colorectal ca should be in differential [thread]
Data by birth cohort
Feb 28, 2020 • 9 tweets • 3 min read
Nice to see PREOPANC published !ascopubs.org/doi/10.1200/JC… some thoughts. Resectability appears different in the paper than the protocol. (1)
Paper- “A tumor without arterial involvement and with venous involvement , 90° was considered resectable; a tumor with arterial involvement , 90° and/or venous involvement between 90° and 270° without occlusion was considered borderline resectable”
